Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 16, 2022; 10(32): 11712-11725
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11712
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11712
Table 1 Baseline characteristics
Parameters | DXM 40 mg treatment (n = 48) | DXM 20 mg treatment (n = 48) | P value |
Age, yr | 69.0 ± 7.2 | 70.0 ± 8.4 | 0.646 |
Gender (male/female) | 26/22 | 30/18 | 0.408 |
DS stage | 0.544 | ||
I | 1 (2%) | 1 (2%) | |
II | 6 (12.5%) | 10 (20.8) | |
III | 41 (85.5%) | 37 (77.2%) | |
ISS stage | 0.791 | ||
I | 8 (16.7%) | 10 (20.8) | |
II | 22 (45.8%) | 19 (39.6%) | |
III | 18 (38.5) | 19 (39.6%) | |
CRP | 13 (27.1%) | 16 (33.3%) | 0.461 |
HGB | 68.0 ± 13.4 | 67.0 ± 14.7 | 0.525 |
Platelet | 13 (27.1%) | 11 (22.9%) | 0.637 |
t(6;14) | 0 | 2 (4.2%) | 0.093 |
t(11;14) | 7 (14.6%) | 8 (16.7%) | 0.779 |
ALT | 4 (8.3%) | 2 (4.2%) | 0.399 |
AST | 7 (14.6%) | 6 (12.5%) | 0.765 |
LDH | 9 (18.6%) | 10 (20.8) | 0.798 |
Cr | 20 (41.7%) | 16 (33.3%) | 0.399 |
UA | 17 (35.4) | 12 (25%) | 0.266 |
Treatment | 0.147 | ||
VRD | 38 (79.2%) | 40 (83.3%) | |
PCD | 10 (20.8) | 6 (12.5%) | |
PD | 0 | 2 (4.2%) |
Table 2 Univariate Cox’s proportional hazard regression analysis of factors affecting progression-free survival
Parameters | P value | HR | 95%CI | |
Lower | Higher | |||
DXM 40 mg vs 20 mg | 0.171 | 0.649 | 0.350 | 1.205 |
Age, yr | 0 | 1.214 | 1.150 | 1.283 |
Gender | 0.821 | 0.930 | 0.497 | 1.740 |
Classification | 0.303 | 0.336 | 0.042 | 2.678 |
DS stage | 0.185 | 1.701 | 0.776 | 3.726 |
ISS stage | 0 | 2.850 | 1.734 | 4.682 |
Platelet | 0.363 | 1.011 | 0.998 | 1.034 |
t(6;14) | 0.586 | 0.048 | 0 | 2739.308 |
t(11;14) | 0.185 | 0.598 | 0.280 | 1.278 |
CRP | 0.175 | 1.010 | 0.995 | 1.025 |
HGB | 0.285 | 0.992 | 0.979 | 1.006 |
ALT | 0.004 | 1.014 | 1.005 | 1.024 |
AST | 0.001 | 1.014 | 1.006 | 1.023 |
ALB | 0.573 | 1.010 | 0.976 | 1.044 |
GLO | 0.702 | 0.998 | 0.985 | 1.010 |
A/G | 0.458 | 0.872 | 0.608 | 1.251 |
LDH | 0.021 | 1.002 | 1.000 | 1.003 |
Ca | 0.652 | 0.982 | 0.909 | 1.062 |
P | 0.907 | 0.980 | 0.701 | 1.37 |
M-protein | 0.982 | 1.000 | 0.996 | 1.004 |
Cr | 0.325 | 1.000 | 1.000 | 1.001 |
UA | 0.169 | 1.001 | 1.000 | 1.002 |
Treatment | 0.009 | 1.913 | 1.173 | 3.119 |
GTA | 0.565 | 0.707 | 0.217 | 2.300 |
IFG | 0.134 | 0.44 | 0.151 | 1.288 |
DM | 0.034 | 2.343 | 1.068 | 5.141 |
Β-CTX | 0.874 | 1.065 | 0.487 | 2.328 |
Osteoporosis | 0.533 | 1.301 | 0.568 | 2.980 |
Hypertension | 0.668 | 1.254 | 0.445 | 3.536 |
TG | 0.716 | 1.156 | 0.529 | 2.525 |
TC | 0.812 | 1.095 | 0.518 | 2.315 |
Acne | 0.965 | 0.977 | 0.348 | 2.746 |
PU | 0.983 | 0.988 | 0.349 | 2.799 |
Insomnia | 0.949 | 1.029 | 0.427 | 2.479 |
Table 3 Multivariate Cox’s proportional hazard regression analysis of factors affecting progression-free survival
Parameters | P value | HR | 95% CI | |
Lower | Higher | |||
Age, yr | 0 | 1.218 | 1.140 | 1.302 |
ISS stage | 0.007 | 2.256 | 1.249 | 4.076 |
ALT | 0.057 | 1.015 | 1.000 | 1.030 |
AST | 0.240 | 1.009 | 0.994 | 1.023 |
LDH | 0.199 | 1.001 | 0.999 | 1.004 |
Treatment | 0.192 | 1.482 | 0.821 | 2.672 |
DM | 0.005 | 3.458 | 1.456 | 8.213 |
Table 4 Univariate Cox’s proportional hazard regression analysis of factors affecting overall survival
Parameters | P value | HR | 95% CI | |
Lower | Higher | |||
DXM 40 mg vs 20 mg | 0.171 | 0.652 | 0.353 | 1.202 |
Age, yr | 0.000 | 1.178 | 1.121 | 1.238 |
Gender | 0.602 | 0.846 | 0.451 | 1.587 |
Classification | 0.14 | 0.211 | 0.027 | 1.665 |
DS stage | 0.067 | 2.271 | 0.944 | 5.462 |
ISS stage | 0.000 | 5.245 | 3.041 | 9.048 |
Platelet | 0.417 | 1.010 | 0.987 | 1.033 |
t(6;14) | 0.489 | 0.046 | 0.000 | 278.970 |
t(11;14) | 0.003 | 0.288 | 0.128 | 0.649 |
CRP | 0.086 | 1.013 | 0.998 | 1.027 |
HGB | 0.050 | 0.983 | 0.967 | 1.000 |
ALT | 0.194 | 1.007 | 0.997 | 1.017 |
AST | 0.070 | 1.008 | 0.999 | 1.016 |
ALB | 0.940 | 1.001 | 0.971 | 1.032 |
GLO | 0.945 | 1.000 | 0.986 | 1.013 |
A/G | 0.911 | 0.957 | 0.668 | 1.371 |
LDH | 0.209 | 1.001 | 0.999 | 1.003 |
Ca | 0.906 | 0.968 | 0.564 | 1.662 |
P | 0.627 | 0.919 | 0.652 | 1.293 |
M-protein | 0.652 | 0.998 | 0.992 | 1.005 |
Cr | 0.623 | 1.000 | 0.999 | 1.001 |
UA | 0.375 | 1.001 | 0.999 | 1.002 |
Treatment | 0.173 | 1.375 | 0.869 | 2.174 |
GTA | 0.546 | 0.694 | 0.212 | 2.271 |
IFG | 0.030 | 0.263 | 0.078 | 0.881 |
DM | 0.203 | 1.661 | 0.760 | 3.631 |
β-CTX | 0.840 | 1.088 | 0.479 | 2.474 |
Osteoporosis | 0.703 | 1.187 | 0.492 | 2.862 |
Hypertension | 0.730 | 1.201 | 0.424 | 3.404 |
TG | 0.642 | 0.823 | 0.363 | 1.869 |
TC | 0.715 | 0.866 | 0.398 | 1.881 |
Acne | 0.995 | 1.003 | 0.354 | 2.842 |
PU | 0.686 | 0.808 | 0.286 | 2.277 |
Insomnia | 0.725 | 1.159 | 0.509 | 2.637 |
Table 5 Multivariate Cox’s proportional hazard regression analysis of factors affecting overall survival
Parameters | P value | HR | 95%CI | |
Lower | Higher | |||
Age, yr | 0 | 1.107 | 1.048 | 1.170 |
ISS stage | 0 | 3.707 | 1.798 | 7.643 |
t(11;14) | 0.055 | 0.399 | 0.156 | 1.019 |
IFG | 0.246 | 0.482 | 0.140 | 1.655 |
Table 6 Comparison two groups with toxicity
Toxicity | DXM 40 mg group | DXM 20 mg group | P value |
Adverse gastrointestinal reactions | 14 | 6 | 0.044 |
GTA | 3 | 5 | 0.426 |
IFG | 4 | 7 | 0.303 |
DM | 3 | 7 | 0.162 |
GTA + TFG + DM | 10 | 19 | 0.033 |
β-CTX | 5 | 12 | 0.049 |
Osteoporosis | 5 | 7 | 0.487 |
Hypertension | 4 | 5 | 0.677 |
TG | 7 | 7 | 0.933 |
TC | 8 | 9 | 0.717 |
Acne | 3 | 6 | 0.267 |
PU | 3 | 4 | 0.654 |
Insomnia | 3 | 11 | 0.017 |
- Citation: Hu SL, Liu M, Zhang JY. Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation. World J Clin Cases 2022; 10(32): 11712-11725
- URL: https://www.wjgnet.com/2307-8960/full/v10/i32/11712.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i32.11712